A fifty-three-year-old contractor came to my Phoenix office in February. He had been on opioid analgesics for chronic low back pain for eleven years. He had had two lumbar surgeries, neither of which had resolved the pain. He had been to four pain management clinics. He was, by the time he reached me, on the maximum approved dose of three concurrent medications and was, in his own words, still in pain every minute of every day.
He had been referred to me by his wife. His wife had read an essay online about male depression. The PCP, the pain specialists, the surgeons — none of them had ever assessed him for depression. He had never been asked, in eleven years of medical care, any version of the question what was happening in your life when this pain started?
I asked it. He paused for a long time. He said: my brother killed himself in 2014. The pain started in early 2015.
His brother had been his best friend, his business partner, and — in his report — the only person he had ever felt fully known by. The brother had used a firearm. The contractor had been the one to find him. He had not, in the eleven years since, talked to a mental health professional about it. He had, instead, talked to surgeons about his back.
His back, on imaging, had real findings. Degenerative disc disease, some mild stenosis. Not, by any reasonable read of the imaging, sufficient to explain the severity, the duration, or the treatment-resistance of his pain.
His PHQ-9, the standard nine-item depression screener, scored 24 out of 27. Severe depression. Eleven years of it, untreated, expressing in his body as a back that no surgery could fix because the back was not, fundamentally, the problem.
This is not an unusual case. It is, in my twenty-six years of clinical practice, an extremely common one. It is, I would argue, the single most under-recognized presentation of male mental health pathology in American primary care.
I want to make the argument carefully, because it is an argument that, if mishandled, becomes harmful.
The argument is not that male chronic pain is fake. It is not. The pain is real. The neurology of chronic pain is well-characterized. Disc disease is real. Arthritis is real. Soft tissue injury is real. The men I see have, in nearly all cases, real physical findings.
The argument is that a meaningful subset — in my conservative estimate, somewhere between thirty and forty percent — of male chronic pain cases in primary care are cases in which untreated depression is functioning as a primary or substantial driver of the pain's severity, duration, and treatment-resistance. The physical finding may have been the precipitating event. The depression is the amplifier. Without addressing the amplifier, the analgesic intervention has limited durable effect.
The literature on this is, by now, robust. Pain and depression share substantial neural overlap — the anterior cingulate cortex, the insula, descending pain modulation pathways. Antidepressants — particularly the tricyclics and SNRIs — have, in multiple controlled trials, produced clinically significant improvement in chronic pain in patients with comorbid depression. The reverse is also true: treating chronic pain often improves depression. The bidirectional relationship is well-established in the academic literature.
What is not well-established — what is, in fact, badly broken — is the translation of that literature into the eight-minute primary care visit, particularly for male patients.
The reasons for the translation failure are structural and gendered.
The DSM criteria for major depressive disorder were operationalized in a research tradition that, in its formative decades, oversampled women. The classic symptom profile — depressed mood, anhedonia, hopelessness, tearfulness, social withdrawal, hypersomnia, appetite changes — is a symptom profile that fits, with high sensitivity, the way women typically present depression in clinical settings. It is a symptom profile that fits, with much lower sensitivity, the way men typically present depression. Men present, in disproportionate numbers, with irritability, anger, somatic complaints (especially pain), new alcohol use, working compulsively, and what the literature has come to call the male depression syndrome — externalizing symptoms that the DSM-5 does not foreground in its primary criteria.
A man with a PHQ-9 of 18 who is denying low mood, denying tearfulness, and presenting with chronic back pain and new heavy drinking will, in many primary care settings, not be screened for depression at all. The screening question — are you feeling sad or depressed? — gets a no. The screen ends. The opioid script begins.
The reimbursement structure rewards somatic workups and discourages psychosocial assessment. An MRI is reimbursable. A thirty-minute conversation about a brother's suicide in 2014 is, in the structured fee schedule, not. A primary care physician under productivity pressure has, structurally, almost no incentive to ask the second question once the first has produced a billable imaging order.
The cultural script around male help-seeking discourages disclosure even when the question is asked. A man who, after fifteen years of overriding, finally walks into a doctor's office for chronic pain has, in many cases, used up the resource he had for help-seeking on the back. He does not have, in the same visit, the additional resource to disclose the suicide, the divorce, the failing business, the father dying. The back is what he can ask for help with. The back is, in this sense, the foothold the man has used to reach medical care. The depression is, under the back, and is, in many cases, the actual reason he came in.
The clinician's job, if we are doing it right, is to look for it. The system, in most cases, does not give the clinician the time, the training, or the incentive to do that looking.
The cost is significant.
It is significant in dollars. Eleven years of inappropriate opioid therapy, two unnecessary lumbar surgeries, four pain management consultations — for one patient — runs to six figures in cumulative healthcare spending. Multiply by the prevalence of the pattern. The under-recognition of male depression presenting as somatic complaint is, in my estimation, one of the larger preventable cost drivers in U.S. ambulatory care.
It is significant in opioids. The American opioid crisis is, in part, a story about male depression that was treated as back pain for two decades. Men prescribed long-term opioid analgesia for chronic pain are, by NIH data, at substantially elevated risk for overdose and for transition to non-prescribed opioids. Many of these men, on assessment, meet criteria for depression that has been continuously untreated through their pain management. The opioid was, functionally, an off-label antidepressant — and a comparatively poor one, with a fatal side effect profile.
It is significant in suicide. Men complete suicide at four times the rate of women in the United States. Men with chronic pain complete suicide at rates several multiples above the male baseline. The intersection — men with chronic pain and untreated depression — is, statistically, one of the highest-risk populations in American medicine. They are, simultaneously, one of the populations least likely to be screened, diagnosed, or treated for the depression that is driving the elevated risk.
The misdiagnosis is, in this sense, not a quiet inefficiency. It is, at scale, a public health catastrophe that the structure of primary care has been ignoring for decades because the structure of primary care was not designed to see it.
What should change.
Routine PHQ-9 screening for all male patients presenting with chronic somatic complaints. This is, in principle, recommended by the USPSTF for all adults; in practice, it is unevenly implemented and rarely repeated. Every man presenting with chronic back pain, chronic GI symptoms, chronic fatigue, new alcohol use, or sexual dysfunction should be screened. A positive screen should trigger, at minimum, a longer follow-up visit and a referral pathway.
Adoption of male-depression-specific screening instruments where available. The Gotland Male Depression Scale, the Male Depression Risk Scale (MDRS-22), and others have been developed precisely because the PHQ-9 underdetects in male populations. These are not in routine clinical use. They should be.
Training in the somatic presentation of male depression for primary care residents. The standard curriculum still treats depression presenting as physical symptoms as an unusual or atypical presentation. In male primary care patients, it is the modal presentation. This needs to be taught, explicitly, and reinforced through case-based learning.
Integrated behavioral health embedded in primary care. The collaborative care model — psychiatric consultation embedded in primary care, with care managers tracking outcomes — has, in multiple controlled trials, substantially improved depression outcomes in primary care populations. It should be the standard of care, not the exception.
A different first question. The single highest-leverage change a primary care physician can make, today, with no additional reimbursement or training, is to add one question to the chronic somatic complaint visit: what was happening in your life when this pain started? The question costs sixty seconds. It does not, in most cases, change the immediate visit plan. It does, in my experience and that of colleagues who have adopted it, surface the second diagnosis in something close to half of male patients with chronic unexplained or treatment-resistant pain.
What patients can do.
If you are a man with a chronic somatic complaint that has not, after months or years of standard workup and treatment, fully resolved, please consider the possibility that you are being treated for half of your diagnosis. The physical finding may be real. There may also be a second diagnosis, untreated, that is amplifying the first.
Take the PHQ-9. It is nine questions. It takes ninety seconds. It is the same instrument your primary care physician would use if they ran it on you, which they often do not. Bring the score to your next appointment. If it is moderate or above, say to your physician: I want to talk about whether depression might be contributing to this pain. The script for raising depression with your primary care doctor walks through several openings.
If your physician dismisses the connection, consider a second opinion. If your physician is open but says they do not have the time to address it, ask for a referral to a behavioral health clinician — ideally one trained in both depression and chronic pain. Many practices now have integrated behavioral health, and the consult does not require leaving your current medical team. The Phoenix depression therapist list includes clinicians experienced in this comorbidity, and similar lists exist for most major cities.
If you are on long-term opioids and have not been screened for depression in the duration of your treatment, this is a conversation to have at your next visit. There are reasonable medical reasons to be on long-term opioids. Unscreened depression for a decade is not one of them. The script for talking to your doctor about medication includes language for this conversation.
If, while reading this, you are recognizing yourself, and the recognition is bringing up the kind of hopelessness that is hard to sit with alone — please call 988. It is free, it is confidential, it is staffed twenty-four hours, and it is, in the world of American men's mental health, the single best resource currently in operation. You do not have to be in immediate crisis to call. You can call to say, I have been carrying this for a long time and I do not know how to bring it to my doctor. They will help you with that conversation.
The back pain is real. The depression is real. The job of medicine, when it is doing its job, is to address both — not because one is more important than the other, but because the body and the mind are, in this presentation, the same address, and the mail has been sitting on the porch, for some of you, for a decade.
Open it.
988 — the national suicide and crisis lifeline — is free, confidential, available 24/7. Call or text. The PHQ-9 is the standard depression screener used in primary care; the script for raising depression with your doctor may help with the appointment conversation. Eduardo Vasquez, PsyD, has been in clinical practice in Phoenix since 1999, with subspecialty focus on chronic pain and comorbid depression. Patient details in this piece have been changed and composited to protect privacy.